![Figure 1. TCD STAT1−/− BM prevents DLI-induced GVHD. All recipients received a miHA-mismatched alloHSCT from either STAT1+/+ or STAT1−/− BM (129 → C3H.SW). Lethally irradiated C3H.SW recipients were transplanted with 4 × 106 TCD STAT1+/+ BM or STAT1−/− BM on day +0. On day +14, 20 × 106 DLI was administered to induce GVHD. Some recipients did not receive a DLI as a negative GVHD control. All mice were followed for (A) clinical GVHD scores. On day +28, all groups were euthanized and immune reconstitution of (B) B cells and (C) Tregs in the spleen was ascertained by flow cytometry. (D) Lethally irradiated C3H.SW recipients were transplanted with 4 × 106 STAT1−/− BM on day +0. On day +14, 0, 10, 20, or 40 × 106 DLI was administered to induce GVHD. Mice were followed for GVHD-associated weight loss. On Day +40, weight loss was compared, and (E) Treg expansion in the spleen was ascertained by flow cytometry. (F) Lethally irradiated recipients received a miHA-mismatched alloHSCT from STAT1+/+ BM (B6 → C3H.SW) treated with vehicle (phosphate-buffered saline [PBS]) or Exenatide (Ex4) for 3 days before alloHSCT. BM recipients continued to receive vehicle or Exenatide for 10 days after alloHSCT. 20 × 106 DLI was administered on day +14 to induce GVHD, and recipients were followed for clinical GVHD scores, and (G) % change in weight was compared at day +40. N = 3 to 7 mice/group, data are representative from 1 of 2 similar experiments. *P < .05, **P < .01, ***P < .001.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/124/12/10.1182_blood-2013-05-500876/4/1976f1.jpeg?Expires=1736058796&Signature=XvUxVU9d2lp5y2MLwrWjMhOu6lxUrSBwFcXLliwPnlQWDRAr628pPNQ3oR82J0ojor09PwT6a4zuNgrOC7df76xenoFempC5xzxxEq1vv546xN3koNGg7~HF9SvT2xswuV9G56YQfe2YZZnow6R5s~9eO4E5ZXEHDcgdaxtL98Xn0jp8F2rjlrsE-YAK7-8C0211m9o~VRUskD6azU4Rjtz0SLu5vasWOIz2JKi8AMW~l7-SorMhjBVceG3AsT91nKd5V9FU9i0EkmNj8sW9EtFUBDwEHfg5omyZgdZjPrzXDz5rtKxhT1gnx9dAdi3PNctmTfGSUFDQikkk7jVNlQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
TCD STAT1−/− BM prevents DLI-induced GVHD. All recipients received a miHA-mismatched alloHSCT from either STAT1+/+ or STAT1−/− BM (129 → C3H.SW). Lethally irradiated C3H.SW recipients were transplanted with 4 × 106 TCD STAT1+/+ BM or STAT1−/− BM on day +0. On day +14, 20 × 106 DLI was administered to induce GVHD. Some recipients did not receive a DLI as a negative GVHD control. All mice were followed for (A) clinical GVHD scores. On day +28, all groups were euthanized and immune reconstitution of (B) B cells and (C) Tregs in the spleen was ascertained by flow cytometry. (D) Lethally irradiated C3H.SW recipients were transplanted with 4 × 106 STAT1−/− BM on day +0. On day +14, 0, 10, 20, or 40 × 106 DLI was administered to induce GVHD. Mice were followed for GVHD-associated weight loss. On Day +40, weight loss was compared, and (E) Treg expansion in the spleen was ascertained by flow cytometry. (F) Lethally irradiated recipients received a miHA-mismatched alloHSCT from STAT1+/+ BM (B6 → C3H.SW) treated with vehicle (phosphate-buffered saline [PBS]) or Exenatide (Ex4) for 3 days before alloHSCT. BM recipients continued to receive vehicle or Exenatide for 10 days after alloHSCT. 20 × 106 DLI was administered on day +14 to induce GVHD, and recipients were followed for clinical GVHD scores, and (G) % change in weight was compared at day +40. N = 3 to 7 mice/group, data are representative from 1 of 2 similar experiments. *P < .05, **P < .01, ***P < .001.
